Keyphrases
Clarithromycin
100%
Stable Coronary Artery Disease
90%
Coronary Artery Disease
64%
Holter Recording
54%
Circadian Variation
54%
12-lead
54%
QT Dispersion
54%
Randomized Placebo-controlled Trial
41%
Antibiotics
36%
Multicenter Trial
32%
Placebo
32%
QT Interval Dispersion
30%
All-cause Mortality
30%
Age-stratified
27%
Breathers
27%
IgG Titer
27%
IgA Antibody
27%
Chlamydophila Pneumoniae
27%
Updated Meta-analysis
27%
Stratified Group
27%
Sex-stratified
27%
Tape Stripping
27%
In Vivo Microdialysis Sampling
27%
Topical Metronidazole
27%
Dock5
27%
Epithelial Invasion
27%
Slow-release Formulations
27%
GIT2
27%
Per Os
27%
Associated Proteins
27%
IgG Antibody
27%
CDKL5
27%
6-year Follow-up
27%
Patients with Coronary Artery Disease
27%
Randomized Trial
27%
Focal Adhesion
27%
Intravenous Bolus
27%
Statin Therapy
27%
5-aminosalicylic Acid (5-ASA)
27%
Antibody Titer
27%
Bioequivalence
27%
Rheostat
27%
Bioequivalent
27%
Pharmacokinetics
27%
Rett Syndrome
27%
Patients with Heart Failure
27%
Antibody Level
27%
Methodological Study
27%
Hazard Ratio
22%
Confidence Interval
22%
Pharmacology, Toxicology and Pharmaceutical Science
Clarithromycin
81%
Ischemic Heart Disease
81%
Placebo
50%
Normal Human
47%
All Cause Mortality
30%
Heart Infarction
30%
Heart Failure
27%
Antibiotic Agent
27%
Coronary Artery Disease
27%
Microdialysis
27%
Bioequivalence
27%
Statin (Protein)
27%
Metronidazole
27%
Aminosalicylic Acid
27%
Pharmacokinetics
27%
Short QT Interval
19%
QT Prolongation
19%
Cardiovascular Mortality
13%
Elimination
7%
Unstable Angina Pectoris
6%
Heart Ventricle Arrhythmia
5%
